Top

Published in:

01-11-2019 | Multiple Myeloma | Original Article

High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany

Authors: Stefan Feiten, Geothy Chakupurakal, Hans Peter Feustel, Michael Maasberg, Burkhard Otremba, Peter Ehscheidt, Manfred Hensel, Richard Hansen, Rudolf Weide

Published in: Supportive Care in Cancer | Issue 11/2019

Abstract

Purpose

Immunomodulatory drugs (IMIDS) have changed the treatment and outcome of patients suffering from multiple myeloma. However, with the oral administration adherence becomes an issue. Since there is no “gold standard” in measuring adherence, we assessed the adherence of myeloma patients with the help of different data sources.

Methods

All patients who have been receiving IMIDS for at least 3 months were eligible. Computer assisted personal interviews of patients and, if possible, their caregivers were carried out. Attending oncologists evaluated the patient’s adherence with the help of a standardized questionnaire. In addition, a retrospective analysis of prescription data was conducted. All data were analyzed statistically using SPSS.

Results

One hundred myeloma patients, 35% female, 65% male, with a median age of 70 years (37–86) were interviewed. Prescription data could be evaluated in terms of adherence in 78 patients (78%), 56 caregivers could be questioned (56%). Ninety-seven percent of patients rated themselves as adherent in taking IMIDS. Data from treating oncologists, caregivers and prescriptions supported this result. IMID therapies were rated as very effective and significant, toxicities were acceptable and dosing regimens simple/uncomplicated.

Conclusions

Myeloma patients seem to be highly adherent to IMID treatments.

Palumbo A, Mina R (2013) Management of older adults with multiple myeloma. Blood Rev 27(3):133–142. https://doi.org/10.1016/j.blre.2013.04.001 CrossRefPubMed

Rajan AM, Kumar S (2016) New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 6(7):e451. https://doi.org/10.1038/bcj.2016.53 CrossRefPubMedPubMedCentral

Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. https://doi.org/10.1056/NEJMra1011442 CrossRefPubMed

Mathes T, Jaschinski T, Pieper D (2014) Adherence influencing factors - a systematic review of systematic reviews. Arch Public Health 72(1):37. https://doi.org/10.1186/2049-3258-72-37 CrossRefPubMedPubMedCentral

McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768. https://doi.org/10.1038/sj.bjc.6604758 CrossRefPubMedPubMedCentral

Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117(14):3733–3736. https://doi.org/10.1182/blood-2010-10-309807 CrossRefPubMedPubMedCentral

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388. https://doi.org/10.1200/jco.2009.26.3087 CrossRefPubMedPubMedCentral

Al-Barrak J, Cheung WY (2013) Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Support Care Cancer 21(8):2351–2357. https://doi.org/10.1007/s00520-013-1831-6 CrossRefPubMed

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, Lennes I, Temel JS, Safren SA, Pirl WF (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376. https://doi.org/10.1634/theoncologist.2015-0405 CrossRefPubMedPubMedCentral

10.

Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56–66. https://doi.org/10.3322/caac.20004 CrossRefPubMed

11.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11(1):44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x CrossRefPubMed

12.

Hohneker J, Shah-Mehta S, Brandt PS (2011) Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 7(1):65–67. https://doi.org/10.1200/JOP.2010.000076 CrossRefPubMedPubMedCentral

13.

Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96. https://doi.org/10.2143/ACB.66.2.2062525 CrossRefPubMed

14.

Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44(5):471–477. https://doi.org/10.1097/01.mlr.0000207817.32496.cb CrossRefPubMed

15.

Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26(5):331–342CrossRef

16.

Banning M (2008) Older people and adherence with medication: a review of the literature. Int J Nurs Stud 45(10):1550–1561. https://doi.org/10.1016/j.ijnurstu.2008.02.009 CrossRefPubMed

17.

Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care 21(1):10–19. https://doi.org/10.1111/j.1365-2354.2011.01295.x CrossRef

18.

Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197. https://doi.org/10.1200/jco.1993.11.6.1189 CrossRefPubMed

19.

Escalada P, Griffiths P (2006) Do people with cancer comply with oral chemotherapy treatments? Br J Community Nurs 11(12):532–536. https://doi.org/10.12968/bjcn.2006.11.12.22424 CrossRefPubMed

20.

Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, Coolbrandt A, Biganzoli L (2017) Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev 57:58–66. https://doi.org/10.1016/j.ctrv.2017.05.002 CrossRefPubMed

21.

Palmieri FM, Barton DL (2007) Challenges of oral medications in patients with advanced breast cancer. Semin Oncol Nurs 23(4 Suppl 2):S17–S22. https://doi.org/10.1016/j.soncn.2007.10.004 CrossRefPubMed

22.

Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J (2004) How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13(1):11–19. https://doi.org/10.1002/pds.819 CrossRefPubMed

23.

Figueiredo Junior AG, Forones NM (2014) Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer. Arq Gastroenterol 51(3):186–191CrossRef

24.

Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497. https://doi.org/10.1056/NEJMra050100 CrossRefPubMed

25.

Zahrina AK, Norsa'adah B, Hassan NB, Norazwany Y, Norhayati I, Roslan MH, Wan Nazuha WR (2014) Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. Asian Pac J Cancer Prev 15(21):9225–9232CrossRef

26.

Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Koppler H, van Roye C, Thomalla J (2016) Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice. SpringerPlus 5:270. https://doi.org/10.1186/s40064-016-1851-z CrossRefPubMedPubMedCentral

27.

Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310CrossRef

28.

Kwiecien R, Kopp-Schneider A, Blettner M (2011) Concordance analysis: part 16 of a series on evaluation of scientific publications. Dtsch Arztebl Int 108(30):515–521. https://doi.org/10.3238/arztebl.2011.0515 CrossRefPubMedPubMedCentral

29.

Baumann W, Welslau M (2017) Patientenadhärenz in der oralen medizinischen Onkologie. Onkologe 23:645–650. https://doi.org/10.1007/s00761-017-0237-3 CrossRef

30.

Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Annals of oncology: official journal of the European society for. Med Oncol 20(3):431–436. https://doi.org/10.1093/annonc/mdn646 CrossRef

31.

Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, von Moos R (2011) Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 80(1–2):29–33. https://doi.org/10.1159/000328317 CrossRefPubMed

32.

Smith AD, Olson C, Lyons B, Tran D, Blackburn DF (2015) Adherence to abiraterone among the first 86 recipients after release in Saskatchewan. Curr Oncol 22(1):64–67. https://doi.org/10.3747/co.22.2219 CrossRefPubMedPubMedCentral

33.

Timmers L, Boons CC, Moes-Ten Hove J, Smit EF, van de Ven PM, Aerts JG, Swart EL, Boven E, Hugtenburg JG (2015) Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer. J Cancer Res Clin Oncol 141(8):1481–1491. https://doi.org/10.1007/s00432-015-1935-0 CrossRefPubMedPubMedCentral

34.

Arber A, Odelius A, Williams P, Lemanska A, Faithfull S (2017) Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study. Eur J Cancer Care 26(2). https://doi.org/10.1111/ecc.12413 CrossRef

35.

Timmers L, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG (2014) Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol (Stockh) 53(2):259–267. https://doi.org/10.3109/0284186x.2013.844353 CrossRef

36.

Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM (2016) Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol 7(5):346–353. https://doi.org/10.1016/j.jgo.2016.07.010 CrossRefPubMedPubMedCentral

37.

Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U (2011) Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 19(7):1009–1018. https://doi.org/10.1007/s00520-010-0927-5 CrossRefPubMed

38.

Schneider SM, Adams DB, Gosselin T (2014) A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol 5(3):163–172PubMedPubMedCentral

39.

Chari A, Bhor M, Eldjerou L, Gilligan AM, Urniasz A, Globe D, Stetsovsky D, Varker H, Davis B, Bonafede M, Talcott J (2018) Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Future Oncol. https://doi.org/10.2217/fon-2017-0727 CrossRef

40.

Cransac ASB, Marty-Quinternet S, Pernot C, Caillot D, Boulin M (2017) DI-053 adherence to immunomodulatory drugs in patients with multiple myeloma. Eur J Hosp Pharm 24:A136–A137

Title: High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany
Authors: Stefan Feiten
Geothy Chakupurakal
Hans Peter Feustel
Michael Maasberg
Burkhard Otremba
Peter Ehscheidt
Manfred Hensel
Richard Hansen
Rudolf Weide
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Hematology
Published in: Supportive Care in Cancer / Issue 11/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04721-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Correspondence between primary and secondary care about patients with cancer: a Delphi consensus study

Health-related quality of life in paediatric patients up to five years post-treatment completion for acute lymphoblastic leukaemia: a systematic review

Predictors of the therapeutic effect of corticosteroids on radiation-induced optic neuropathy following nasopharyngeal carcinoma

Depression as mediator and or moderator on the relationship between hopelessness and patients’ desire for hastened death

The efficacy of the ganglion impar block in perineal and pelvic cancer pain

Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer